Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. At $285.00, A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG.
Bio-Rad Laboratories is a multinational life science (40% of 2025 net sales) and clinical diagnostics (60%) company selling instruments, reagents, and consumables in 36+ countries. Approximately 60% of net sales came from international locations, with Europe as the largest... Read more
Sell if holding. At $285.00, A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG. Chart setup: Death cross but MACD improving, RSI 51. Score 5.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Bio-Rad Laboratories, Inc.
Latest news
- Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Up - Here's Why - MarketBeat — MarketBeat positive
- Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year - Yahoo Finance — Yahoo Finance positive
- Are Options Traders Betting on a Big Move in Nuvation Bio Stock? - TradingView — TradingView positive
- Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com — Investing.com negative
- Bio-Rad (BIO) Reports Strong Q1 Revenue Amidst Market Challenges - GuruFocus — GuruFocus positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational locations60%10-K Item 1: 'We generated approximately 40% of our consolidated net sales for the year ended December 31, 2025 from the U.S. and approximately 60% from our international locations'
- HIGHcounterpartySartorius AG10-K Item 1A: 'Changes in the market value of our position in Sartorius AG will continue to materially impact our consolidated statements of income (loss) and other financial statements'
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02LOWAt April 21, 2026 annual meeting, stockholders approved amended Bio-Rad 2017 Incentive Award Plan adding 335,000 shares (to 5,535,000 total) and extending expiration to March 18, 2036.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $285.00, A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG. Chart setup: Death cross but MACD improving, RSI 51. Prior stop was $262.09. Score 5.6/10, moderate confidence.
Take-profit target: $306.59 (+8.8% upside). Prior stop was $262.09. Stop-loss: $262.09.
Concentration risk — Geographic: international locations (60.0%); Concentration risk — Counterparty: Sartorius AG; Analyst target reached - limited upside remaining.
Bio-Rad Laboratories, Inc. trades at a P/E of 41.2 (forward 25.1). TrendMatrix value score: 5.8/10. Verdict: Sell.
10 analysts cover BIO with a consensus score of 3.6/5. Average price target: $293.
What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories is a multinational life science (40% of 2025 net sales) and clinical diagnostics (60%) company...
Bio-Rad Laboratories is a multinational life science (40% of 2025 net sales) and clinical diagnostics (60%) company selling instruments, reagents, and consumables in 36+ countries. Approximately 60% of net sales came from international locations, with Europe as the largest international region; the company also holds a $5.67B fair-value equity stake in Sartorius AG that materially impacts financial results.